Послеоперационная ускоренная химиолучевая терапия злокачественных глиом головного мозга
Диссертация
Однако вопрос об оптимальном объеме операции широко обсуждается специалистами. Несмотря на значительный прогресс современных методик нейровизуализации, инфильтративный рост злокачественных глиом, а также наличие обширной зоны отека часто делают невозможным четкое выделение и отграничение опухоли от нормальной ткани головного мозга. Именно поэтому ряд нейрохирургов выступает за выполнение операции… Читать ещё >
Список литературы
- Абрамов В.В. Взаимодействие иммунной и нервной системы // Новосибирск 1988. — С. 165.
- Адо А.Д. О взаимодействиях нервной и иммунокомпетентной системк механизмам влияния нервной системы на лимфоциты) // Вестник АМН СССР. 1993. — № 7. — С. 48−51.
- Виноградов В.М., Жаринов Г. М. Профилактика и лечение лучевых осложнений // В кн.: Лучевая терапия в онкогинекологии и онкоурологии./ Под ред. А. М. Гранова и В. Л. Винокурова. СПб.: Фолиант, 2002. — С.284
- Гуськова А.К. Нервная система человека, вовлеченного в радиационную аварию: дозы-эффекты в отдаленные сроки // Материалы 2-й
- Чернобыльинтеринформ, 1998. С. 220.
- Гуськова А.К. Радиация и мозг человека // Актуальные и прогнозируемые нарушения психического здоровья после ядерной катастрофы в Чернобыле: Матер, междунар. конф., г. Киев, 24−28 мая, 1995. Киев: Ассоциация «Врачи Чернобыля», 1995. — С. 22.
- Гуськова А.К., Баранов А. Е. Гематологические эффекты у подвергшихся облучению при аварии на Чернобыльской АЭС // Мед. радиология. 1991.309.1. Международной последствияконференции «Отдаленные Чернобыльской катастрофы"медицинские1. Киев:8. С.31−37.: 111
- Иваницкая Н.Ф.у Нейроэндокринные нарушения у лиц, подвергшихся ионизирующему излучению после аварии на ЧАЭС, в отдаленные сроки // Ликарськая^ справка. -1992. G. 35−37.
- Касаткин-BiH: Теория! сновидений: — Mi: Медицина. 1972. — С. 328.
- Коновалов1 Л. Н. Первичные опухоли у пожилых // Вестн. АМН СССР.— 1980:-№ 12:-С.4а-44:
- Коновалов A. Hi, Корниенко- В.Н., Пронин? И.И. Магнитно-резонансная томография в нейрохирургии. -М-: Видар. 1997. — С.23.
- Костеников Н. А-, Фадеев? Н- II., Тютин. Л. А. Возможности позитронной эмиссионной томографии- с новым» отечественным: РФ11 11С: бутиратомшат-рия в нейроонкологии // Медицинская радиология и радиационная безопасность. 2006. — № 6. — С. 13−23.
- Логановский К. Н., Нягу А. И. Характеристика психических расстройств у пострадавших вследствие Чернобыльской катастрофы в свете международной-классификации-- болезней 10-го пересмотра // Социальная и клиническая психиатрия.,-1995. № 2. -С. 15−23.
- Лосев Ю. А. Эпидемиология первичных опухолей головного мозга в сельской местности (на, модели- Ленинградской области): Автореф. дис. канд. мед. наук. CI16., 2003. — С.2−5.
- Малыгин В. Л-, Тарасов А. Ю., Тюрева Л. В. Структура и: динамикам первичной заболеваемости: и инвалидности среди участников ликвидации' аварии на Чернобыльской АЭС // Вестник новых медицинских- технологий. 1996.-№ 4.-С. 83−90.
- Марри Р., Греннер Д., Майес П., Родуэлл В. Биохимия человека в 2 томах.// М.: Мир. 1993. — Том 1. — С. 225−298.
- Марченко С.В. Комплексное лечение злокачественных глиом полушарий большого мозга: Автореф. дис. канд. мед. наук. СПб., 1997. — С.2−7.
- Марченко С.В., Комплексное лечение глиальных опухолей головного мозга. // Вопросы онкологии. 1997. — № 43(8). — С.610−612.
- Мацко Д. Е., Коршунов А. Г. Атлас опухолей центральной нервной системы. Спб.: изд-во РНХИ им. A. JI. Поленова, 1998. — С. 277.
- Насонова В.А., Иванова М. М. Актуальные проблемы нейроиммунологии // Вестник АМН СССР. 1994.- № 1. — С.4−7.
- Никитин М.П. Основные вопросы клиники опухолей головного мозга.// Труды II Всесоюзного съезда психиатров и невропатологов. М., 1936. -С. 287−300.
- Никифоров Б.М., Мацко Д. Е. Опухоли головного мозга. СПб. Изд. «Питер», 2003. — С.15−16.
- Новиков В.И., Карандашов В. И., Сидорович И. Г. Иммунотерапия при злокачественных новообразованиях М.: Изд. Медицина, 2002. — С.18.
- Пуссеп Л.М. Общая симптоматика опухролей головного мозга. Рвота.// Руководство по неврологии: В 8 т. / Под ред.С. Н. Давиденкова. М.: Медгиз, 1961. — Т.5. — С.118.
- Раздольский И.Я. Опухоли головного мозга JL: Медгиз, 1954. — С. 12−14.
- Савченко А. Ю., Новиков В. П., Левочко Е. Д., Комбинированное и комплексное лечение опухолей головного мозга нейроэктодермального происхождения // Вестник рентгенологии и радиологии 1996. — № 4. — С.141−148.
- Савченко Ю.А. Глиомы головного мозга (эпидемиология, диагностика, дифференцированное лечение и реабилитация). Омск: Изд. ОмГТТУ, 1997.- С. 8−9- 60−67.
- Сергеев П.В., Поляев Ю. А., Юдин А. Л., Шимановский Н. Л. Контрастные средства. М.: Известия, 2007. — С. 496.
- Скворцова Т.Ю., Бродская З. Л., Рудас М. С. с соавт. Сравнительная оценка радиофармпрепаратов, в ПЭТ-диагностике опухолей головного мозга // Медицинская визуализация. 2001. — № 1. — С 67−74.
- Скворцова Т. Ю., Рудас М. С., Бродская 3. Л., с соавт. Новые критерии в позитронно-эмиссионно-томографической диагностике глиом головного мозга с использованием 11С-метионина // Вопр. нейрохир. 2001. — № 2. -С. 12−16.
- Тарханов- И.Р. О физиологическом действии рентгеновских лучей на центральную нервную систему// Больнич. газета Боткина. 1896. — № 33. -С.753.
- Трон Е.Ж. Заболевание зрительного пути.: Л.: Медицина, 1968. С.30−39.
- Улитин А. Ю. Эпидемиология первичных опухолей головного мозга среди населения крупного города и пути совершенствования организации медицинской помощи больным с данной патологией //Автореф. дисс. .канд. мед. наук. СПб., 1997. — С. З^.
- Хаитов P.M. и др. Проблемы нейроиммунологии // Рос. мед. журнал. 1997.- № 3. С. 42−47. }
- Ъ1 Хилько В. А, Скоромец А. А., Корытова Л. И. и др. Опухоли ствола головного мозга СПб.: Гиппократ, 2005. — С. 415.
- Холодова Н. Б., Кузнецова Г. Д., Зубовский Г. А. Отдаленные последствия лучевого воздействия на нервную систему // Жур. невр. и психиат. им. Корсакова. 1996. — № 5. — С. 29−33.
- Шеперд Г. Нейробиология М.: Мир. — 1987.- Т.1.-С.454.
- Штернберг Э.Я. Геронтологическая психиатрия, М., Медицина. — 1977. -С. 140−151.
- Ярмоненко С.П., Вайнсон А. А. Радиобиология человека и-животных, М.: Высшая школа, 2004. — С.463−466
- Altman D. Practical statistics for medical research // Ed. Chapman and Hall. -1990.-612 p.
- Ammirati M., Vick N., Liao Y., et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas // J. Neurosurgery. 1987. — Vol.21. — P. 201−206.
- Ang К. K., Jiang G.L., Feng Y., et al. Extent and kinetics of recovery of occult spinal cord injury // Int. J. Radiat. Oncol. Biol. Phys. 2001. — Vol.50>— P.1013−1020.
- Aronen H.J., Pardo F.S., Kennedy D.N., et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas // Clin. Cancer Res. 2000. — Vol.6. — № 6. — P.2189−2200.
- Ashby L.S., Shapiro W.R. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study // J. Neurooncol. -2001.-Vol.51.-P.67−86.
- Barker F.G., Chang S.M., Valk P.E., Pounds T.R., et al. 18Fluorodeoxyglucose Uptake and Survival of Patients with Suspected Reccurent Malignant Glioma // Cancer. 1997. — Vol.1. — P. 115−126.
- Basso U., Ermani M., Vastola F. et al. Non-cytotoxic therapies for malignant gliomas // J. Neurooncol. 2002.- Vol.58.- P. 57−69.
- Bauman G.S., Caspar L.E., Fisher В .J., et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme// Int. J. Radiat. Oncol. Biol. Phys. 1994 — Vol.29. — P. 835−839.
- Beith J., Cook R., Robinson В., Levi J., et al. Modulation of resistance to BCNU by-depleting MGMT activity with procarbazine in patients with gliomas // Cancer Chem. Pharm. -1996.- Vol.37. P.522−524.
- Belanich M., Randall Т., Pastor M.A., et al: Intracellular localization and intracellular heterogeneity of the human DNA repair protein Об-methylguanine-DNA methyltransferase // Cancer Chem. Pharm. 1996 — Vol.37. — P.547−555.
- Bergmann S.R., Weinheimer C.J., Markham J., Herrero P. Quantitation of myocardial fatty acid metabolism using PET // J. Nucl. Med. 1996. -Vol.37. -№ 10.-P. 1723−1730.
- Bergsma J. Illness, the mind, and the body: Cancer and immunology: An introduction // Theor. Med. 1994. -Vol. 15, № 4. — P. 334−347.
- Bernstein M., Bampoe J. Low-grade gliomas // Neurooncology. The Essentials. -NewYork, 2000. Ch. 30. — P. 302−308.
- Bernstein M., et al. // Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project // J. Neurosurg. 2004. — Vol. 100 (6). — P.1132−1133.
- Bigner S.H. et al. Gene amplification in malignant human gliomas: clinical and histopathologic aspects // J. Neuropathol Exp. Neural. 1988. -Vol.47. — P.191−205.
- Black K. L., Cloughesy Т., Huang S. C., et al: Intracarotid infusion of RMP7 bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas // J. Neurosurg. -1997.- Vol.86. P. 603- 609.
- Blacklock JB, Grimm EA. Lymphokine-activated killer lymphocytes: LAK and interleikin-2 in the treatment of malignancies of the central nervous system // Immunol Ser. 1989. — Vol.48 — P.93−99. ¦ 116 •
- Bobo R. Hi, Laske D.W., Akbasak A. ct al. Convectionenhanced delivery of macromolecules in the brain-// Proc. Natl. Acad. Sci. USA. -1994. Vol. 91- P. 2076−2080.
- Boiardi A., Eoli M-, Salmaggi A. ct al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours // J. Neurooncol: 2001. -Vol.54. — P.39−47.
- Bouchard J. Radiation Therapy of Tumors and Diseases of the Nervous System // Philadelphia. PA: Lea & Febiger — 1966. — P.250−257
- Bower M., Newlands E. S., Bleehen N. M., et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma // Cancer Ghem. Pharm. 1997. — Vol.40 — P.484 — 488.
- Brada M., Hoang-Xuan K., Rampling R. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma: multiforme at first relapse //Ann. Oncol. 2001. — Vol.12-P. 259−266.
- Brandes A.A., Ermani M., Turazzi S. et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study // J. Clin. Oncol. -1999. Vol.17- P.645−650.
- Brem S.S., Bierman P.J., Black P., Blumenthal D.T., et al Central nervous system cancers: Clinical Practice Guidelines in Oncology// J. Natl. Compr. Cane. Netw.- 2005. -Vol.3 (5). -P.644−690.
- Brown P.D., Ballman K.V., Rummans T.A., et al. Prospective study of quality of life in adults with mewly diagnosed high-grade gliomas // J: Neurooncol. 2006- Vol. 76. P. 283−291.
- Bucy P.C., Oberhill H.R., Siqueira E.B., Zimmerman H.M., et al. Cerebral glioblastomas can be cured! //Neurosurgery. 1985. — Vol.16 (5).-P.714—715. .117. • •
- Burger P., Heinz E., Shibata Т., et al. Topographic anatomy and CT correlations. in the untreated glioblastoma multiforme // J. Neurosurg. 1988.-Vol.68. — P. 698−704.
- Burger P., Kleihues P. Cytologic composition-of the untreated glioblastoma with implications for evaluation' of needle biopsies // Cancer. .1989: — Vol.63. -P.2014−2023.
- Caimcross JIG., Ueki- K., Zlatescu M.C. et- al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas // J: Natl. Cancer. Inst. 1998: — Vol:90: — P.1473−1479.
- Cha S., Knopp E.A., Johnson -G. et al. Dynamic contrast-enlianced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplain AJNR // Am: JlNeuroradiolL- 2000: Vol:21. — P!-881−890h
- Chamberlain M.C., Kormanik P, Salvage chemotherapy with paclitaxel for recurrent primary brain.tumors. // J- Clin. Oncol. 1995. — Vol: 13. — P.2066 -2071.
- Chandler K^.E.,.Prados^Ml. D?, Malec Mt, .WilsomCi В. bong-tenm survival in patients with-glioblastoma multiforme // Neurosurg. 1985. — Vol.16 (5). -P.714−717.
- Chang E.L., Yi W., Allen P.K., et al. Hypofractionated radiotherapy for elderly or younger low performance status glioblastoma patients: outcome and prognostic factors:// Int- J- Radiat- Oncol: Biol. Phys. 2003. Vol.56 — P.519−528.
- Chang S., Nicholas- M.K., Larson D. et al. Phase II study of concurrent- temozolomide (TMZ) and. cis-retinoic acid (CRA) with- radiation (RT) for newly diagnosed glioblastoma multiforme // Neurooncol: 2002. -Vol.4. -P.366.
- Chang S.M., Barker F.G., Huhn S.L. et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma // J. Neurooncol. 1998.-Vol.37-P. 169−176.
- Chen Y.R., Li W.X., Lin Y.R., Chen L.H. Value of 18F-FDG PET imaging in diagnosing tumor resid intracranial dlioma after surgery and radiotheraphy // Ai. Zheng. 2004. — Vol.23. — № 10. — P.1210−1212.
- Ciric I., Rovin R., Cozzens J., et al. Role of surgery in the treatment of malignant cerebral gliomas. In: Apuzzo M, ed. Malignant Cerebral Glioma. Park Ridge // American Ass. of Neurolog. Surg. 1990. — P. 141−153.
- Cloughesy T. F., Black K. L., Gobin Y. P. et al. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas // J. Neurosurgery. 1999. — Vol.44. -P. 270−278.
- Cloughesy T.F., Filka E., Nelson G .et al. Irinotecan treatment foi- recurrent malignant glioma using an every-3-week regimen // Am. J. Clin. Oncol. 2002. -Vol.25.- P.204−208.
- Coffey R., Lunsford L., Taylor E. Survival after stereotactic biopsy of malignant gliomas // Neurosurgery 1988. — Vol.22. — P.465−473.
- Couldwell W. Т., Hinton D. R., Sumock A. A. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen // Clin. Cancer Res. -1996. Vol.2. — P. 619−622.
- Curran W., Jr., Scott C., Horton J., et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci. A report from three radiation therapy oncology group (RTOG) trials // J. Neurooncol. 1992. -Vol.12.-P. 219−227.
- Curran WJ. Jr., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials // J. Nad. Cancer. Inst. 1993. — Vol.85. -P. 704−710.
- Dalbasti Т., Oktar N., Cagli S. et al. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study // J. Neurooncol 2002. — Vol.56. -P. 167−174.
- Dantzer R.J., Wollman E. Molecular mechanisms of fever: the missing link // Eur.J.Netw. 1998. — V.9(l). — P.27−31.
- De Witte O, Lefranc F, Levivier M, et al. FDG-PET as a prognostic factor in high-grade astrocytoma // J. Neurooncol. 2000.- V. 49(2). — P. 157−163.
- Deutsch M., al. Polyamines in brain tumor therapy // J. Neurooncol. -1995-Vol.25(2). P. 167−179.
- Di Lorenzo N., Palma L., Nicole S. Lymphocytic infiltration in long-survival glioblastomas: possible host’s resistance //Acta. Neurochir. (Wien). 1977-Vol.39.-P.27−33.
- Dillman R.O., Shea W.M., Tai D.F. et al. Interferon alpha-2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma // Neurooncol. 2001. -Vol.3.-P. 35−41.
- Do V., Gebski V., Barton M.B., The effect of waiting for radiotherapy for grade IIIAV gliomas // Radiother. Oncol. 2000. — Vol.57(2). — P.131−136.
- Dropcho E.J., Rosenfeld S.S., Vitek J. et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas // J. Neurooncol. 1998. — Vol.36. — P. 191−198.
- Esteller M., Garcia-Foncillas J., Andion E. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents 11 N. Engl. J. Med. 2000. — Vol.343. — P. 1350−1354.
- Fabry Z., Raine C.S., Hart M.N. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS // Immunol. To day. — 1994. -Vol.15. -P.218−224.
- Fadul C., Wood J., Thaler H., et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas // Neurology -1988. -Vol. 38 P. 1374—1379.
- Fallai C., Olmi P. Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases) // Radiother Oncol. 1997. — Vol. 43. — 235−246.
- Feun L.G. Wallace S. Stewart DJ. et al: Intracarotid infusion of cis-diamminedichloroplatmum in the treatment of recurrent malignant brain tumors // Cancer. -1984.- Vol.54. P.794−799.
- Fewer D., Wilson С. В., Boldrey E. B. et al. The chemotherapy of brain tumors: clinical experience with carmustine (BCNU) and vincristine // JAMA. 1972. -Vol.222. — P. 549−552.
- Fine H.A., Dear K.B.G., Loeffler J.S. et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults // Cancer -1993. Vol.71. — P. 2585−2597.
- Fine H.A., Figg W.D., Jaeckle K. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas // J. Clin. Oncol. -2000. Vol.18. — P.708−715.
- Finn G. P., Bozek Т., Souhami R. L. et al. High-dose etoposide in the treatment of relapsed primary brain tumors //Cancer Treat. Rep. -1985. -Vol.69. P.603−605.
- Fitzek M. M., Thornton A. F., Rabinov J. D., et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastomamultiforme: results of a phase П- prospective trial // J. Neurosurg. 1999. -Vol.91. -P.251−260.
- Florell R.C., Macdonald D.R., Irish W.D., et al." Selection bias, survival, and brachytherapy for glioma // J. Neurosurg. -1992. Vol.76. — P.179−183.
- Folstein M., Folstein S., McHugh R. Mini-mental state. A practical method for grading the cognitive state of patients of clinican // J.Psychiatr.Res. 1975. -Vol.12.-P.189−198
- Friedman H.S., Kokkinakis D: M., Pluda. J. et all Phase I trial, of 06-benzylguanine for patients undergoing surgery^ for malignant glioma // J. Clin. Oncol. 1998. — Vol. 16. — P.3570−3575.
- Friedman H.S., Petros W.P., Friedman A.H. et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma // J. Clin. Oncol. 1999. -Vol.17. -P.1516−1525.
- Friedman H.S., Pluda J., Quinn J.A. et al. Phase I trial of carmustine plus 06-benzylguan for patients with recurrent or progressive malignant glioma // J. Clin. Oncol. 2000. — Vol.18. — P. 3522−3528.
- Fulton D., Urtasun R-, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP 16) for patients with recurrent malignant glioma // J. Neurooncol. -1996.-Vol.27.-P.T49−155:
- Garden A. S., Maor M. H., Yung W. K., et al. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas // Radiother. Oncol. 1991. — Vol.20. — P. 99−110.
- Gilbert M. R., Friedman H. S., Kuttcsch J. F. et al. A phase II study of temozolomide in. patients with newly diagnosed supratentorial malignant glioma before radiation therapy // Neurooncol. 2002. — Vol.4. — P. 261−267.
- Groothuis D.R. Warnke P.C., Molnar P., Lapin G.D. Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors // J. Neurosurg. 1990- - Vol.72. — p.441−449.
- Hagge R. Jl, Wong: T. Z., Goleman R. E. Positron emission- tomography: brain tumors and- lung cancer // Radiol. Glin. North. Am. 2001. — Vol. 39 (5). — P: 871−881. •.
- Hahn G-A-, Dunn R-H-, Logue P.E., et al. Prospective study of neuropsychologic testing and quality of life assessment of adults with primary malignant brain tumors // lilt. Ji Radiat: Oncol. Biol: Phys. 2003. — Vol.55. — P. 992−999.
- Hasegawa B. Hi, Iwata K., Wong R. Hi, et al: Dual modality imaging of functioniand. physiology // Acad: Radiol: 2002.- Vol.9. — P. 1305−1321.
- Huang A.Y. et al. Bone marrow derived cells present MHC class I restricted Штоиг antigens- in priming of апйШтоиг immune responses // Giba Found Symp. 1994. Vol.187. — P. 229−240.
- Jackson R., Fuller G., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gUomas // Neuro-Oncology 2001. — Vol.3 — P. 193−200.
- Jaeckle K., Yung W.K., Prados M. et al. NABTC 98−03: Phase n evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma //J. Neurooncol 2000. -Vol.2.- P.271.
- Jeremic В., Shibamoto Y., Grujicic D., et al. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study // J. Neurooncol. 1999. — Vol.44. — P. 85−90.
- Kaba S.E. Kyritisis A.P., Conrad C. et al: The treatment of recurrent cerebral gliomas with all trans retinoic acid (tretinoin) // J. Neurooncol. 1997. — Vol. 34 -P. 145−151.
- Karnofsky D.A., Abelmann W.H., Craver L.F. et al. The use of nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma // Cancer. 1948. — Vol.1 — P.634 — 656.
- Kelly P., Daumas-Duport C., Kispert D., et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms // J. Neurosurg. -1987. -Vol.66. P. 865 — 874.
- Kelly P. Computed tomography and histologic limits in glial neoplasms: Tumor types and selection for volumetric resection // Surg. Neurol. 1993. — Vol.39. -P.458.
- Khafaga Y.M., Jamshed A., Allam A.A., et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy // Acta. Oncol. -1999. Vol.38. -P.lll-116.
- Khayat D., Giroux В., Berille J. et al: Fotemustine in the treatment of brain primary tumors and metastases // Cancer Invest. 1994. — Vol.12. — P.414 — 420.
- Kim H.K., Thornton A.F., Greenberg H.S., et al. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy // Am. J. Clin. Oncol. 1997. — Vol.20(4). — P. 358−363.
- Kitahara Т. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor // J. Neurooncol. 1987. — Vol.4. — P.329−336.
- Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment related factors on midterm to long term cognitive squealed in low grade gliomas: a comparative study // Lancet 2002. — Vol.360. — P. 1361−1368.
- Kondziolka-D., Lunsford L. The role of stereotactic biopsy in the management of gliomas // J. Neurooncol. -1999. -Vol.42. P. 205−213.
- Kreth F., Warnke P., Scheremet R., et al. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme // J. Neurosurg. 1993. -Vol.78. — P.762−766.
- Kubler-Ross E. Factors influencing cosmetic results after conservation therapy for breast cancer // Int. J. Radiat. Oncol. Biol. Phys. 1994. — Vol. 31. — P. 753 -763.
- Lacroix M., Abi-Said D., Foumey D., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival // J. Neurosurg. 2001. — Vol.95. — P.190 — 198.
- Lane B. A, Mosely I.F., Theron J. Intracranial tumors // Diagnostic Radiology / Eds R.G. Grainger, D.J. Allison. Edinburgh: Churchill Livingstone, 1992. -Vol. 3. — P.1935.
- Lang F., Gilbert M., Puduvalli V., et al. Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies // J. Neuro-Oncology 2002. — Vol.4. — P.268−277.
- Larson G-L., Wilbanks J. Hi, Dennis W.S., et ali. Interstitial, radiogold'. implantation for- the treatment of recurrent high-grade gliomas // Cancer. 1990)-Vol.66.-P. 27−29.
- Laske D. W., Youle R. J, Oldfield- E. Hi Tumor regression with regional distribution of the targeted toxin TF CRM 107 im patients with- malignant brain tumors // Natt MedL- 1997. Voli3. — P- 1362−1368:
- Lee SiW., Fraass B.A., Marsh L.H., et al: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study // Int: J. Radiat. Oncol. Biol: Phys. 1999. — Vol.43. — P.79−88.
- Levin V., Yung A., Prados M: et al: Phase II study of temodal (temozolamidel at first relapse in anaplastic astrocytoma patients // Proc. ASCO. -1997. — P.2−10.
- Levin V.A., Wara W.M., Davis R.L. et al. Phase III comparison of BCNU and the- combination of procarbazine, CCNU, and' vincristine administered after radiotherapy with hydroxyurea for malignant gliomas // J. Neurosurg. 1985. -Vol.63.-P.218−223.
- Levitt R, Buckner J.C., Cascino T.L. et al: Phase II study of amonafide in patients with recurrent glioma // J. Neurooncol. 1995'. — Vol.23. — P. 87- 93.
- Liang B.C., Thornton A.F. Jr., Sandier H.M., et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy // JlNeurosurg.- 1991. Vol.75. — P. 559 — 563.
- Lieberman- D.M., Laske D.W., Morrison P.F. et al. Convection enhanced distribution of large molecules in gray matter during interstitial drug infusion // J. Neurosurg. 1995. — Vol. 82. — P. 1021−1029.
- Lillehei K.O., Mitchell" DiH., Johnson" S. D- et al. Long-term follow up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy // Neurosurgery. 1991. — Vol.28. — P. 16−23.
- Loeffler J.S., Alexander E., 3rd, Hochberg F.H., et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas // Int. J. Radiat. Oncol. Biol. Phys. 1990. — Vol.19. — P. 1455 -1462.
- Longee D.C., Friedman H.S., Albright R.E. et al: Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine // J. Neurosurg. 1990.- Vol.72. P.583−588.
- Lote K., Egeland Т., Hager В., Stenwig В., et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients // J. Clin. Oncol. 1997. — Vol. l5(9). — P.3129 — 3140.
- Lowe W.L. Jr., Meyer Т., Karpen C.W. et al. Regulation of insulin-like growth factor I production in rat C6 glioma cells: possible role as an autocrine paracrine growth factor // Endocrinology. 1992. — Vol. 130. — P. 2683−2691.
- Lucas G.L., Luxton G., Cohen D., et al. Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors // Int. J. Radiat. Oncol. Biol. Phys. 1991. — Vol.21. — P. 715−721.
- Macdonald D., Cairncross G., Stewart D., et al: Phase П study of topotecan in patients with recurrent malignant glioma // Ann. Oncol. 1996. Vol.7. — P. 205 207.
- Mahaley Jr. M.S., Mettlin C., Natarajan N., et al: National survey of patterns of care for brain-tumor patients // J. Neurosurg. 1989. — Vol. 71. — P. 826−836.
- Malkin M.G. Interstitial brachytherapy of malignant gliomas: the Memorial Sloan-Kettering Cancer Center experience // Recent Results in Cancer Research. -1994.-Vol.135.-P. 117−125.
- Mankoff D.A., Bellon J.R. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond // Semin. Radiatin. Oncol. 2001. — Vol. 11.(1).- P. 16−27.
- Marquette C., Ceccaldi P.E., Alteration of IL-1 production and IL-la binding sites in mouse brain during rabies infection // Archives of Virol. — 1996. — Vol. 141.- № 3−4.- P.573−585
- Marx G.M., Pavlakis N., McCowatt S. et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme // J. Neurooncol. 2001. -Vol.54.-P. 31−38.
- Massey V., Wallner K.E., Patterns of second recurrence of malignant astrocytomas. // Int. J. Radiat. Oncol. Biol. Phys. 1990. — Vol.18. — P.395−398.
- McDermott M.W., Sneed P.K., Gutin P.H. Interstitial brachytherapy for malignant brain tumors // Semin. Surg. Oncol. 1998. — Vol.14. — P.79−87.
- Merchant R.E., Merchant L.H., Cook S.H. et al. Intralesional infusion of lymphokine-activated killer (LAK) cells and-recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor // Neurosurgery 1988. -Vol.23.-P. 725−732.
- Meyer P. Т., Schreckenberger M, Spetzger U. et all. Comparison of visual and ROI-based" brain tumour grading using 18F-FDG PET: ROC analyses // Eur. J: Nucl. Med. 2001. — Vol: 28. (2). — P.165−174.
- Micali G., LinthicumK., Han N., et al. Increased5 risk of erythema multiforme major with- combination anticonvulsant and" radiation therapies // Pharmacotherapy 1999. — Vol.19. — P.223−227.
- MRCBTWE Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research ouncil trial // J. Clin. Oncol. 2001. — Vol.19. — P.509−518.
- Murayama K. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides // J. Immunother. -2000. Vol.23. — P.511−518.
- Napolitano M., Keime-Guibert F., Monjour A. et al. Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase ILstudy // J. Neurooncol. 1999. — Vol.45. — P.229−235.
- Nazzaro J., Neuwelt E. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults // J: Neurosurg. 1990: -Vol.73.-P.331−344.
- Newlands E.S., O’Reilly S.M., Glaser M.G., et al. The Charing Cross hospital experience with temozolamide in patients with gliomas // Eur. J. Cancer. 1996. -Vol.32. — P.2236−2241.
- Newton H.B., Slivka M.A., Stevens C.L. et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas // J. Neurooncol. 2002. — Vol.56. — P.79 — 86.
- Nitta Т., Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas // Cancer 1995. — Vol.75. -P.2727−2731.
- Nonaka Y. et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors // Tissue Antigens 2002. — Vol.60. — P.319 — 327.
- Norman C., Dickson D. The aftermatch of Chernobil.// Scence. 1986, Vol. 72. -P. 1111−1143
- Okano F., Storkus W.J., Chambers W.H. et al. Identification of a novel HLA-A0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain // Clin. Cancer Res. 2002. — Vol.8. -P.2851−2855.
- O’Reilly S.M., Newlands E.S., Glaser M.G., et al: Temozolamide: A new oral cytotoxicchemotherapeutic agent with promising activity against primary brain tumours // Eur. J. Cancer. 1993 — 29. — P. 940−942.
- Padma M.V., Said S., Jacobs M., et al. Prediction of pathology and survival by FDG PET in gliomas // J. Neurooncol. 2003. — Vol. 64.(3). — P. 227−237.
- Palma L., Di Lorenzo N., Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas: incidence, fate, and relevance to prognosis in 228 operated cases // J. Neurosurg. 1978 — Vol.49. — P. 854−861.
- Pannullo S., Balmaceda C., Serventi J. et al. Temozolomide plus celecoxib for treatment of malignant gliomas // Neurooncol. 2002. — Vol.4. — P. 373−374.
- Patchell R.A., Regine W.E., Ashton P. et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. // J. Neurooncol. 2002. — Vol.60. — P. 37.
- Patel S., Breneman J.C., Warnick R.E., et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme // J. Neurosurgery 2000. — Vol.46. — P. 1123−1128.
- Peterson K., Harsh G., Fisher P.G. et al. Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma // J. Neurooncol. -2001.-Vol.53.-P. 27−32.
- Philippon J.H., Clemenceau S.H., Fanchon F.H. et al. Supratentorial low-grade atrocytomas in adults // Neurosurgery. — 1993. Vol.32. — P. 554−559.
- Phuphanich S., Ferrall S., Greenberg H. Long-term survival in malignant glioma. Prognostic factors // J. Fla. Med. Assoc. 1993. — Vol. 80(3). — P.181−184.
- Phuphanich S., Scott C., Fischbach A.J., Langer C., at al. A phase II radiation oncology group study (RTOG 91−13) in patients with recurrent malignant glioma // J. Neurooncol. 1997. — Vol. 34. — P. 193−200.
- Pirzkall A., McKnight T.R., Graves E.Ii., et al. MR-spectroscopy guided target delineation for- high-grade gliomas // Int. J- Radiat. Oncol. Biol. Phys. 2001. -Vol.50.-P.915−928.
- Prados M., Gutin P., Phillips Т., et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1−9897/ Int. J: Radiat. Oncol. Biol. Phys. -1992.-Vol.23.-P. 3−8.
- Prados M.D., Schold S.C., Spence A.M., et al: Phase II< study of paclitaxel in patients with recurrent malignant glioma // J. Glin. Oncol. 1996. — Vol.14. -P.2316- 2321.
- Purdy J.A., Dose-volume specification: new challenges with intensity-modulated radiation therapy // Semin. Radiat. Oncol. 2002. — Vol, 12. — P.199−209.
- Quattrocchi K.B. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of, recurrent malignant gliomas // J. Neurooncol. 1999. -Vol.45.-P. 141−157.
- Quigley M., Maroon J. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas // J. Neurosurgery -1991.-Vol. 29 P.385−389.
- Reagan T.J., Bisel H.F., Childs D.S. Jr. et al. Controlled study of CCNU and radiation therapy in malignant astrocytoma // J. Neurosurg. 1976. — Vol.44. -P. 186−190.
- Rock J.R. Pilocytic astrocytoma and other indolent tumors // Neurooncology. The Essentials. New York, 2000. — Ch. 32. — P. 319−327.
- Rodriguez L.A., Prados M., Silver P. et al. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors // Cancer. -1989. Vol.64. — P.2420−2423.
- Rogers L.R., Purvis J.B., Ledermann R.J., et al: Alternating sequential intracarotid BCNU and cispaltin in recurrent malignant glioma // Cancer. 1991.- Vol.68.-P.15−21.
- Rosenberg S.A. The development of new immunotherapy for the treatment of cancer using interleukin-2. A review // Ann. Surg. 1988. — Vol. 208. — P. 121— 135.
- Rostom A.Y., Sunderland K., Re-irradiation of astrocytoma of the brain // Br. J. Radiol. 1989. — Vol.62. — P. 173−174.
- Ruhlmann J., Oehr P., Biersack H.J. PET in Oncology. Springer Verlag. Berlin-Heidelberg Germany. 1999. P.25
- Salazar O.M., Rubin P., Feldstein M.L., et al. High dose radiation therapy in the treatment of malignant gliomas: final report // Int. J. Radiat. Oncol. Biol. Phys. -1979. Vol.5. — P. 1733−1740.
- Salcman M., Scholtz H., Kaplan R.S., Kulik S. Long-term survival in patients with malignant astrocytoma // Neurosurgery. 1994. — Vol.34(2). — P.213−219.
- Sandberg-Wollheim M, Malmstrom P, Stromblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4 // Cancer 1991. — Vol.68.- P.22−29.
- Sawaya R., Hammoud M., Schoppa D., et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors // Neurosurgery. 1998. — Vol.42. — P. 1044−1056.
- Scharfen C.O., Sneed P.K., Wara W.M., et al. High activity iodine-125 interstitial implant for gliomas // Int. J. Radiat. Oncol. Biol. Phys. 1992. -Vol.24. -P.583−591.
- Schelssinger J. Cell signaling by receptor tyrosine kinases // Cell. 2000. -Vol.103.-P. 211−225.
- Shapiro W.R., Green S.B., Burger P.C. et al. A randomized comparisomof intraarterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma // J. Neurosurg. 1992. -Vol.76.-P. 772−781.
- Sheleg S.V., Korotkevich E.A., Zhavrid E.A. et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme // J. Neurooncol. 2002. — Vol.60. -P. 53−59.
- Shi W., Wildrick D., Sawaya R. Volumetric measurement of brain tumors from MR imaging // J. Neurooncol. 1998. — Vol.37. — P. 87−93.
- Short S.C., Traish D., Dowe A. et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas // J. Neurooncol. 2001. — Vol.51. — P. 41−45.
- Sklansky B.D., Mann-Kaplan R.S., Reynolds A.F. Jr. et al. Proceedings: 4-demethyl-epipo-dophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intra-cranial neoplasms // Cancer 1974. — Vol. 33. — P. 460−467.
- Slminen E., Nuutinen J.M., Huhtala S., Multivariate analysis of prognostic factors in 106 patients with malignant glioma // Eur.J. Cancer 1996. — Vol. 35 (11). -P.1918−1923.
- Sneed P.K., Gutin P.H., Larson D.A. et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost // Int. J. Radiat. Oncol. Biol. Phys. 1994. — Vol.29. — P. 719−727.
- Son В., Kim M., Choi В., et al. Proton magnetic resonance chemical shift imaging directed stereotactic biopsy // Acta Neurochir (Wien). 2001. -Vol.143.-P. 45−50.
- Stewart D.J. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors // J. Neurooncol. 1994. — Vol.20 — P. 121−139.
- Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials // Lancet -2002. Vol.359. -P. 1011−1018.
- Straathof C.S.M., Van den Bent MJ., Ma J., et al: The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor // J. Neurooncol. 1998.- Vol. 37.- P. 1−8.
- Strange K. S" Kerr L.R., Andrews H.N. e.al. // Neurotoxicol. Teratol. -2000. -Vol.22(1). P. 89−102:251: Strauss L.G., Conti P: S: The Application of PET in Clinical Oncology II J: Nucl. Med: 1991. — Vol.32(4). — P.623−648.
- Stupp R., Dietrich P.Y., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide // J.Clin. Oncol. 2002. -Vol.20.-P. 1375−1382.
- Tang C.K., Gong X.Q., Moscatello D.K. et al. Epidermal growth factor receptor vIII enhances tumorigemcity in human breast cancer. // Cancer Res. -2000. Vol.60. -P.3081−3087.
- Taylor B.V., Buckner J.C., Cascino T.L., et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma // J.Clin.oncology Vol 16(6). — 1998. — P. 2195−2201.
- Torres I.J., Mundt A.J., Sweeney P.J., et al. A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors // Neurology 2003 -Vol.60.-P.1113−1118.
- Tsuda N et al. UDP-Gal: betaGlcNAc betal:3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour // Br. J. Cancer 2002. — Vol.87. -P. 1006−1012.
- Tubiana J.M.et al. The natural history of breast cancer: implications for a screening strategy // Int. J. Radiat. Oncol. Biol. Phys. 1990 — Vol. 19(5). — P. 1117−1120.
- Valtonen S., Timonen U., Toivanen P. et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study // Neurosurgery 1997. — Vol.41. — P.44−48.
- Van den Bent M.J., Schellens J.H.M., Vecht Ch.J., et al: Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas // Eur. J. Cancer 1998. -Vol.34. -P. 1570−1574.
- Vecht C., Avezat C., Van Putten W, et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospectiveanalysisin 243 patients // JtNeuroli NeurosurgPsychiatry- 1990i- Vof53.- Pi 466−471. '
- Vidal J. Influence of the specific immune response on some consistent murine behaviors // J: GemPsychoK 1999i-Voli 126(2). — P: 205−216-
- Vigliani-M:C., Sichez N., Poisson M-, et al:.A prospective study of cognitive functions following conventional1 radiotherapy for- supratentorial gliomas in young adults: 4-year results // Int. J- Radiat. Oncol. Biol- Phys. —1996- Vol.35. — P.527−533.
- Walker M.D., Strike T.A., Sheline G-E. An analysis of dose-effect relationship in, — the radiotherapy of malignant gliomas // Int: J. Radial- Oncol- Biol- Phys. —1979.- Vol.5. P. 1725−1731.
- Walker M.D., Strike T.A. An evaluation- of methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma // Proc. Am. Assoc. Cancer. Res. 1976. — Vol.17. — P.163.
- Walter K.A., Tamargo R.J., Olivi A., Burger P.C., et al. Intratumoral chemotherapy // Neurosurgery 1995. — Vol. 37. — P. 1129−1145.
- Warnick R.E., Prados M.D., Mack E.E. et al. A phase П study of intravenous carboplatin for the treatment of recurrent gliomas // J. Neurooncol. 1994. -Vol.19.-P. 69−74.
- Warnke P.C. Blasberg R.G., Groothuis D.R. The effect of hyperosmotic blood-brain-barrier disruption on blood-to-tissue transport in ENU-induced gliomas // Ann. Neurol. 1987. — Vol. 22. — P. 300−305.
- Wen P.Y., Alexander E., Black P.M., et al. Long term results of stereotactic brachytherapy used in the initial' treatment of patients with glioblastomas // Cancer. 1994. -Vol. 73. — P. 3029−3036.
- WHO Handbook for reporting results of cancer treatment // WHO offset publication № 48. Geneva: World Health Organization, 1979. -P. 129.
- Wrensh M.K., Minn Y., Bondy M.L. Epidemiology // Neurooncology. The Essentials. New York, 2000: — Ch. I. — P. 2 — 17.
- Yung W.K., Albright R.E., Olson J: et al. A phase IT study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse // Br. J. Cancer. 2000. — Vol. 83. — P.588−593
- Yung W.K., Kyritsis A.P., Gleason M.J. et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid // Clin. Cancer Res. 1996. — Vol. 2. -P. 1931−1935.
- Yung W.K., Mechtler L., Gleason M.J. Intravenous carboplatin for recurrent malignant glioma: a phase II study // J. Clin. Oncol. 1991- Vol.9. -P. 860−864.
- Yung W.K.A. Temozolomide in malignant gliomas // Semin. Oncol. 2000. -Vol.27. — P. 27−34.